OncoDNA Closes €19 Million Series B, Furthering its Support for Cancer Patients

OncoDNA, located in Gosselies, Belgium, has landed €19 million Series B funding. The healthtech startup, founded in 2012, is a leader in personalised molecular analysis for cancer patients. OncoDNA’s technology assists medical doctors in determining a treatment path and provides improved monitoring of tumour evolution in patients. With this round of funding secured, the startup has big plans.

OncoDNA is in the process of developing software which provides oncology clinical decision support. This technology will aid molecular laboratories, healthcare proffesionals and the pharma industry become more efficient in the areas of research and clinical practice.

Led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank, with the support of SFPI-FPIM, the funding will support rapid international growth, hiring initiatives and software development.

Source: EU-Startups

Ken McDonnell
Born in Dublin, Ireland, Ken holds a Masters in Film History & Philosophy and has been involved with the world of media since moving to Berlin in 2014. He was an editor for a video game website for many years and is now the editorial manager at StartupTV. His areas of expertise include AR, VR and machine learning.

More from author

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!